References
- Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guideline. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147–71. Erratum, Hepatology 2004;40:269.
- Dienstag JL, McHutchinson JG. AGA technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231–64
- Bruguera M, Bañares R, Córdoba J, Jardí R, González-Lahoz J, Ladero JM, et al. Documento de consenso de la AEEH sobre el tratamiento de las infecciones por los virus de las hepatitis B y C. Gastroenterol Hepatol 2006; 29(Suppl 2)216–30
- Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 989–94
- Konnick EQ, Williams SM, Ashwood ER, Hillyard DR. Evaluation of the COBAS hepatitis C virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assay. J Clin Microbiol 2005; 43: 2133–40
- Witthöft Th, Möller KH, Wiedmann KH, Mauss St, Link R, Lohmeyer J, et al. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: the German Open Safety Trial. J Viral Hepatitis 2007; 14: 788–96
- Distante S, Bjøro K, Hellum KB, Mirvang B, Berg JP, Skaug K, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002; 22: 269–75
- Lee SS, Bain VG, Peltekian K, Krajdens M, Yoshida EM, Deschenes M, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23: 397–408
- Economou M, Milionis H, Filis S, Baltaviannis G, Christou L, Elisaf M, , et al. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007; Epub ahead of print.
- Foster GR, Fríed MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD) and ribavirin. Scand J Gastroenterol 2007; 42: 247–55
- Mihm U, Herrmann C, Sarrazin C, Zeuzem S. Predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006; 23: 1043–54
- McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–9
- Marcellin P, Hadziyannis SJ, Berg T, Sánchez-Tapias JM, Bronowicki J-P, Sakai T, et al. Virological response at 4 and 12 weeks predicts high rates of sustained virological response in genotype 1 patients treated with peginterferon α-2a (40 kD) plus ribavirin. J Hepatol 2007; 46(Suppl 1)S231–2
- Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL, Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425–33
- Fríed MW, Shiffman ML, Reddy R, Smith C, Marinos G, Gonçales F, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82
- Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086–7
- Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46: 1688–94
- Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the “accordion” regimen?. J Hepatol 2007; 47: 580–7
- Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA are web 4 of treatment. Gastroenterology 2006; 131: 451–60